Having trouble accessing articles? Reset your cache.

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

How Apple Tree assembled suite of technologies to address challenges that limit other gene therapies

With a $75 million series A investment, and Biogen veteran Michael Ehlers joining newly launched Limelight Bio as CEO, Apple Tree Partners believes a multiplatform approach to gene therapy can overcome limitations of the modality and address diseases previously untreatable via that method.

“We’re building a multidisease, multiplatform company to tackle some big gaps in genetic therapy,”

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers